Amylin Pharmaceuticals says a federal court issued an injunction preventing drug development partner Eli Lilly from using the same sales force to sell an Amylin-developed diabetes treatment and a competitor's.
Amylin says the temporary restraining order prevents Lilly from continuing with a plan to sell both Byetta and Boehringer Ingelheim's linagliptin. Amylin and Lilly entered an agreement in 2002 to develop and sell Byetta, a type 2 diabetes treatment.
Lilly also entered a development agreement with Germany's Boehringer Ingelheim in January. Earlier this month, regulators approved linagliptin, which also treats type 2 diabetes. Amylin then filed a lawsuit against Lilly over that arrangement.
Lilly says it is disappointed in the court's decision but will take the necessary steps to comply with the order.